Rise and shine, everyone, another busy day is on the way. We can tell because the short person scooted for the local schoolhouse and the official mascots are spending more time than usual fertilizing the Pharmalot grounds. As for us, we are enjoying a warm and shiny sun and, of course, a few cups of stimulation. All of which is to say that the time has come to get cracking. On that note, here are some items of interest to help you along. Have a wonderful day and do keep us in mind when interesting developments emerge …

Express Scripts (ESRX) is pressing drug makers with a new type of migraine treatment to forgo the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates, according to Reuters. The pharmacy benefit manager, which hopes the move alleviates political pressure, is also seeking a refund if the drugs fail to work within a defined timeframe. Amgen (AMGN) expects a drug to be approved next month, followed by similar medicines from Teva Pharmaceutical (TEVA) and Eli Lilly (LLY) that the companies say could benefit up to 4 million people in the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy